Alves Marta R, Isenberg David A
Internal Medicine, Department of Medicine, Centro Hospitalar Universitário do Porto, Porto, Portugal.
Division of Medicine, Centre for Rheumatology, University College of London, Room 424, 4th Floor, Rayne Building, 5 University Street, London, WC1E 6JF, UK.
Clin Exp Med. 2020 May;20(2):159-166. doi: 10.1007/s10238-020-00606-7. Epub 2020 Mar 4.
Mixed connective tissue disease was first described as a new autoimmune rheumatic disease in 1972 based on the claim of a distinct clinical picture associated with anti-RNP antibody positivity. Subsequently, this new entity has divided opinions in the rheumatology community. We have reviewed recent cohort studies with more than 100 patients, comparing the clinical and immunological features, treatment, prognosis and evolution to well-defined autoimmune rheumatic diseases. We also reviewed clinical features of undifferentiated autoimmune rheumatic diseases based on the most recent studies. After gathering and reviewing these data, we discuss whether the designation "mixed connective tissue disease" should be maintained.
混合性结缔组织病于1972年首次被描述为一种新的自身免疫性风湿性疾病,其依据是声称存在与抗RNP抗体阳性相关的独特临床表现。随后,这一新实体在风湿病学界引发了不同观点。我们回顾了近期针对100多名患者的队列研究,比较了其临床和免疫学特征、治疗、预后以及向明确的自身免疫性风湿性疾病的演变情况。我们还根据最新研究回顾了未分化自身免疫性风湿性疾病的临床特征。在收集和回顾这些数据后,我们讨论了“混合性结缔组织病”这一名称是否应继续保留。